BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| Peramivir Trihydrate | Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. Uses: Antiviral agents. Synonyms: BCX-1812; RWJ-270201; S-021812; BCX 1812; RWJ 270201; S 021812; BCX1812; RWJ270201; S021812. Grades: >98%. CAS No. 1041434-82-5. Molecular formula: C15H28N4O4.3H2O. Mole weight: 382.45. |  |
| Pergolide Mesylate | Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist. Uses: Dopamine agonists. Synonyms: PERGOLIDE MESYLATE; 66104-23-2; Permax; Pergolide Methanesulfonate; PERGOLIDE MESYLATE SALT; Pergolide mesilate; Pergolide (mesylate); LY127809; Pergolidemesylate; NSC-319773; NSC-758442; UNII-55B9HQY616; CHEBI:8021; pergolide monomesylate; LY 127809; LY-127809; 55B9HQY616; pergolide monomethanesulfonate; MLS000069837; MPE; Pergolide mesylate [USAN:USP]; DTXSID6040583; 8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate; 8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate; 8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate; NSC319773; NSC 319773; NSC 758442; CPD000058504; SMR000058504; Pergolide mesilate (JAN); Permax (TN); Ergoline, 8-((methylthio)methyl)-6-propyl-, monomethanesulfonate, (8beta)-; Ergoline, 8-beta-((methylthio)methyl)-6-propyl-, methanesulfonate (1:1). Grades: >98%. CAS No. 66104-23-2. Molecular formula: C19H26N2S·CH4O3S. Mole weight: 410.59. | |
| Perhexiline maleate salt | Perhexiline maleate salt is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor. It is an anti-anginal metabolic modulator and used in treatments for angina. It inhibits the mitochondrial enzyme CPT-1 and to a lesser extent CPT-2. It was also recently found to inhibit the activity of mTORC1. It has been listed. Uses: Perhexiline maleate salt is an anti-anginal metabolic modulator and used in treatments for angina. Synonyms: Pexid;(Z)-but-2-enedioic acid;2-(2,2-Dicyclohexylethyl)piperidine maleate;(+/-)-2-(2,2-Dicyclohexylethyl)piperidine Maleate. Grades: 98%. CAS No. 6724-53-4. Molecular formula: C23H39NO4. Mole weight: 393.56. | |
| Perindopril | Perindopril is a long-acting ACE inhibitor. It is used to treat patients with hypertension, diabetes mellitus type 2, coronary heart disease, chronic heart failure or stable coronary artery disease in form of perindopril arginine on the basis of a large evidence. lt has anticancer activity through the inhibition of tumor growth and angiogenesis in hepatocellular carcinoma cells. It suppresses angiotensin II production in vitro. In the in vitro cell proliferation assays, it does not show significant effect on the cell proliferation. In vivo assays demonstrate it can suppress the growth of SCC-VII cells. It is reported that 8 mg perindopril given orally can lower blood pressure without a change in heart rate. It was developed by Xoma. Uses: Perindopril is used to treat patients with hypertension, diabetes mellitus type 2, coronary heart disease, chronic heart failure or stable coronary artery disease in form of perindopril arginine. lt has anticancer activity through the inhibition of tumor growth and angiogenesis in hepatocellular carcinoma cells. Synonyms: MCNA-2833;S-9490; MCNA 2833;S 9490; MCNA2833;S9490; (2S-(1(r*(r*)), 2-alpha, 3a-beta, 7a-beta))-oxopropyl); Octahydro-1-(2-((1-ethoxycarbonyl)butyl)amino)-1-11h-indole-2-carboxylicaci; Coversyl; Perindoprilum; Prestarium; 1-[2-(1-Ethoxycarbonylbutylamino)propanoyl]-2, 3, 3a, 4, 5, 6, 7, 7a-octahydroindole-2-carboxylic acid 2-methyl-2-propanamine (1:1);(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid. Grades: 95%. CAS No. 82834-16-0. Molecular formula: C19H32N2O5. Mole weight: 368.47. | |
| Perlapine | Perlapine, an atypical neuroleptic, is a potent and selective hM3Dq DREADD agonist (EC50 = 2.8 nM) with >10,000-fold selectivity for hM3Dq over hM3. Perlapine blocks dopamine and serotonin (5-HT) receptors (Kis = 60, 30, and 30 nM for D2, D4, and 5-HT2A, respectively). Synonyms: 6-(4-Methyl-1-piperazinyl)-11H-dibenz[b,e]azepin; AW 14-2333; HF 2333; Hypnodin;6-(4-methylpiperazin-1-yl)-11H-benzo[c][1]benzazepine. Grades: >98%. CAS No. 1977-11-3. Molecular formula: C19H21N3. Mole weight: 291.396. | |
| PETCM | PETCM is an activator of caspase-3 and a stimulator of apoptosome formation in HeLa cell cytosols. It acts via inhibition of the oncoprotein ProT, therefore stimulates apoptosome formation and subsequent caspase-3 activation in a cytochrome c-dependent manner. Synonyms: α-(Trichloromethyl)-4-pyridineethanol. Grades: ≥99% by HPLC. CAS No. 10129-56-3. Molecular formula: C8H8Cl3NO. Mole weight: 240.52. | |
| PF 00356231 | PF 00356231 is a MMP-12 inhibitor, and at high concentrations it also inhibits other MMPs. Synonyms: PF 00356231; PF00356231; PF-00356231; (3R)-3-phenyl-3-[[4-(4-pyridin-4-ylphenyl)thiophene-2-carbonyl]amino]propanoic acid. Grades: 98%. CAS No. 766536-21-4. Molecular formula: C25H20N2O3S. Mole weight: 428.5. | |
| PF-03654746 Tosylate | PF-03654746 Tosylate is a histamine H3 receptor antagonist undergoing a clinical trial for attention-deficit hyperactivity disorder (ADHD) therapy. Uses: Potential treatment of adhd. Synonyms: Trans-N-Ethyl-3-fluoro-3-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]-cyclobutanecarboxamide 4-methylbenzenesulfonate; PF-03654746, 4-Methylbenzenesulfonate. Grades: 99%. CAS No. 1039399-17-1. Molecular formula: C18H24F2N2O.C7H8O3S. Mole weight: 494.59. | |
| PF-03814735 | PF-03814735 is an orally bioavailable, ATP-competitive, reversible small-molecule Aurora kinase inhibitor with potential antineoplastic activity. Aurora kinase inhibitor PF-03814735 binds to and inhibits Aurora kinases A and B, which may result in the inhibition of cellular division and proliferation in tumor cells that overexpress these kinases. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control during mitosis. Synonyms: PF03814735; PF-03814735; PF 03814735. Grades: >98%. CAS No. 942487-16-3. Molecular formula: C23H25F3N6O2. Mole weight: 474.48. | |
| PF-04171327 | PF-04171327 is a dissociated agonist of the glucocorticoid receptor (DAGR), which is a selective high-affinity partial agonist of the GR. It has potent anti-inflammatory activity at exposures which provide less undesirable effects on bone and glucose metabolism. It is used to the treatment of rheumatoid arthritis. It was developed by Pfizer and was terminated in clinic phase 2. Uses: Pf-04171327 has potent anti-inflammatory activity. it is used to the treatment of rheumatoid arthritis. Synonyms: PF-04171327; PF04171327; PF 04171327; PF-4171327; PF4171327; PF 4171327; Fosdagrocorat;(2R,4aS,10aR)-4a-benzyl-7-((2-methylpyridin-3-yl)carbamoyl)-2-(trifluoromethyl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-2-yl dihydrogen phosphate. Grades: >98 %. CAS No. 1044535-58-1. Molecular formula: C29H30F3N2O5P. Mole weight: 574.53. | |
| PF04191834 | PF04191834 is a novel, potent and selective non-redox 5-lipoxygenase(5-LOX) inhibitor with an IC50 value of 229 +/- 20 nM. It inhibits 5-LOX in human blood cells with an IC80 value of 370 +/- 20 nM. It exhibits good potency in enzyme- and cell-based assays, as well as in a rat model of acute inflammation. It demonstrated approximately 300-fold selectivity for 5-LOX over 12-LOX and 15-LOX and shows no activity toward the cyclooxygenase enzymes. It is effective in inflammation and pain. Uses: Pf04191834 is effective in inflammation and pain. Synonyms: PF-04191834; PF04191834; PF 04191834; PF-4191834; PF4191834; PF 4191834. 4-(3-((4-(1-Methyl-1H-pyrazol-5-yl)phenyl)thio)phenyl)tetrahydro-2H-pyran-4-carboxamide. Grades: >98 %. CAS No. 1029317-21-2. Molecular formula: C22H23N3O2S. Mole weight: 393.51. | |
| PF-04217903 | PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays an important role in inflammation, angiogenesis, and tumor cell migration and proliferation. Synonyms: PF-04217903; PF 04217903; PF04217903; PF-4217903; PF4217903; PF 4217903. Grades: >98%. CAS No. 956905-27-4. Molecular formula: C19H16N8O. Mole weight: 372.392. | |
| PF-04217903 methanesulfonate | PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed more than 1000-fold greater selectivity against c-Met kinase over 150 other kinases. It displays similar potency to inhibit the activity of c-Met-H1094R, c-Met-R988C, and c-Met-T1010I, but has no inhibitory activity against c-Met-Y1230C. It showed antitumor activity in tumor models where c-Met is activated by mechanisms including c-Met gene amplification, HGF/c-Met autocrine loop formation or c-Met overexpression. It suppressed proliferation of c-Met-amplified GTL-16 and H1993cells. It induced apoptosis in GTL-16 cells. It inhibited the phosphorylation of c-Met and suppressed tumor growth. Synonyms: PF-04217903 methanesulfonate; PF 04217903 methanesulfonate; PF04217903 methanesulfonate. Grades: >98%. CAS No. 956906-93-7. Molecular formula: C20H20N8O4S. Mole weight: 468.49. | |
| PF-04447943 | PF-04447943 is a potent, selective brain penetrant PDE9 inhibitor (Ki of 2.8, 4.5 and 18 nM) for human, rhesus and rat recombinant PDE9 respectively and high selectivity for PDE9 versus PDEs1-8 and 10-11. Synonyms: PF-04447943; PF 04447943; PF04447943; PF-4447943; PF 4447943; PF4447943. Grades: >98%. CAS No. 1082744-20-4. Molecular formula: C20H25N7O2. Mole weight: 395.46. | |
| PF 04449613 | PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cGMP with the PDE9 inhibitor PF-04449613 increases synaptic calcium activity and learning-dependent synaptic plasticity. Synonyms: (R)-6-(1-(3-Phenoxyazetidin-1-yl)ethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one; 1,5-Dihydro-6-[(1R)-1-(3-phenoxy-1-azetidinyl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-4H-pyrazolo[3,4-d]pyrimidin-4-one, 6-[(1R)-1-(3-Phenoxyazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; PF 4449613; PF 9613; PF4449613; PF9613; PF-4449613; PF-9613. Grades: ≥98% by HPLC. CAS No. 1236858-52-8. Molecular formula: C21H25N5O3. Mole weight: 395.45. | |
| PF-04620110 | PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM. Synonyms: PF-04620110; PF 04620110; PF04620110. PF-4620110; PF 4620110; PF4620110. Grades: >98%. CAS No. 1109276-89-2. Molecular formula: C21H24N4O4. Mole weight: 396.44. | |
| PF 04628935 | PF 04628935 is a potent antagonist/inverse agonist of the ghrelin receptor, growth hormone secretagogue receptor 1a (GHS-R1a) with an IC50 of 4.6 nM. It is orally bioavailable and exhibits reasonable brain penetration. Synonyms: 1-[2-[[2-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl]methyl]-2,7-diazaspiro[3.5]non-7-yl]-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone; PF-04628935; PF04628935; PF 04628935; PF-4628935; PF4628935; PF 4628935. Grades: ≥98% by HPLC. CAS No. 1383719-97-8. Molecular formula: C24H26ClN7OS. Mole weight: 496.03. | |
| PF-04634817 | PF-04634817 is a dual CCR2/CCR5 antagonist, which can be used to treat diabetic nephropathy and diabetic macular edema. Synonyms: PF-04634817; 1228111-63-4; UNII-51M3FB9B9E51M3FB9B9E[(1S,3R)-3-[[(3S,4S)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1S,4S)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone. CAS No. 1228111-63-4. Molecular formula: C25H36F3N5O3. Mole weight: 511.6. | |
| PF 04671536 hydrochloride | PF 04671536 is a highly potent and selective inhibitor of phosphodiesterase 8B (PDE8B) phosphodiesterase 8A (PDE8A) (IC50= 1.3 and 1.9 nM, respectively), with selectivity for PDE8A/B over other PDEs (IC50 values are >10 μM) and a range of other targets. Synonyms: PF-04671536 hydrochloride; PF04671536 hydrochloride; PF 04671536 hydrochloride; PF-04671536 HCL; PF04671536 HCL; PF 04671536 HCL; PF04671536HCL; 5-Methyl-3-[[(2R)-4-(2-thiazolylmethyl)-2-morpholinyl]methyl]-3H-1,2,3-triazolo[4,5-d]pyrimidin-7-amine hydrochloride. Grades: ≥98% by HPLC. CAS No. 1305116-67-9. Molecular formula: C14H18N8OS.HCl. Mole weight: 382.87. | |
| PF-04856264 | This active molecular is a human Nav1.7 voltage gated sodium channel inhibitor with the IC50 value of 28 nM. PF-04856264 inhibits the Nav channel by interacting with the S1-S4 voltage sensor segment of homologous domain 4 which is unlike other known NaV inhibitors. PF-04856264 interaction with the region of the channel which controls voltage sensitivity enables subtype selective modulation and may be applicated as an efficient tool for drug development. Synonyms: PF-04856264; PF04856264; PF 04856264; PF-4856264; PF4856264; PF 4856264. 3-cyano-4-(2-(1-methyl-1H-pyrazol-5-yl)phenoxy)-N-(thiazol-2-yl)benzenesulfonamide. Grades: 98%. CAS No. 1235397-05-3. Molecular formula: C20H15N5O3S2. Mole weight: 437.49. | |
| PF 04885614 | PF 04885614 is a potent and selective Nav1.8 inhibitor (IC50 = 53 nM for human NaV1.8 channel), with selectivity for hNaV1.8 over hNaV1.6, hNaV1.7, hNaV1.1, hNaV1.2 and hNaV1.5 (IC50= 4.2, 7.0, 11, 16 and 27 μM respectively). Synonyms: PF 04885614; PF04885614; PF-04885614; 1-Methyl-[1-[4-(4-trifluoromethoxy)phenyl]-imidazol-2-yl]-ethanamine. Grades: ≥98% by HPLC. Molecular formula: C13H14F3N3O. Mole weight: 285.26. | |
| PF-04929113 | PF-04929113, also known as SNX-5422, is a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5542 is rapidly converted to SNX-2112, which accumulates in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses. Synonyms: (1r,4r)-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl glycinate; SNX5422; SNX-5422; SNX 5422; PF4929113; PF-4929113; PF 4929113; PF04929113; PF 04929113; PF-04929113. Grades: >97%. CAS No. 908115-27-5. Molecular formula: C25H30F3N5O4. Mole weight: 521.53. | |
| PF-04929113 mesylate | The methlate salt form of PF-04929113 that has potential antineoplastic activity targeting Hsp90. It could probably result in the proteasomal degradation of oncogenic client proteins and the restrain of tumor cell proliferation. Uses: The methlate salt form of pf-04929113 that has potential antineoplastic activity targeting hsp90. Synonyms: PF-04929113 mesylate; PF 04929113 mesylate; PF04929113 mesylate; (1r,4r)-4-((2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)phenyl)amino)cyclohexyl glycinate mesylate; PF-04929113 mesylate; SNX5422; SNX-5422; SNX 5422; PF4929113; PF-4929113; PF 4929113; PF04929113; PF 04929113; PF-04929113. Grades: 98%. CAS No. 1173111-67-5. Molecular formula: C26H34F3N5O7S. Mole weight: 617.64. | |
| PF-04937319 | This active molecular is a glucokinase activator originated by Pfizer and EC50 value is 174 nM. PF-04937319 can improve glycemic control in adults with type 2 diabetes when applicated in conjunction with metformin and it can also maintain lower-glucose levels without it resulting in hypoglycemia. However,clinical trials were discontinued for Type 2 diabetes mellitus in 2016. Uses: Type 2 diabetes mellitus. Synonyms: PF-04937319; PF04937319; PF 04937319; PF-4937319; PF 4937319; PF4937319; N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide. Grades: 98%. CAS No. 1245603-92-2. Molecular formula: C22H20N6O4. Mole weight: 432.44. | |
| PF-04942487 | PF-4942847 is a novel oral Hsp90 inhibitor, which is a candidate for clinical development in TNBC by collaboratively targeting multiple signaling pathways. In addition, AKT degradation in PBLs may serve as a biomarker in clinical development. Synonyms: PF4942847; PF 4942847; PF-04942847. Grades: >98%. CAS No. 1046859-34-0. Molecular formula: C20H18Cl2F3N7O2. Mole weight: 516.31. | |
| PF-04991532 | This active molecular is a hepatoselective glucokinase activator that reduces MDG (mean daily glucose), FPG (fasting plasma glucose) and glucose excursion in humans. PF-04991532 may offer glycemic control without inducing hepatic steatosis. PF-04991532 was developed by Pfizer but was discontinued in Phase-II for Type-2 diabetes mellitus in USA in 2012. Uses: Type 2 diabetes mellitus. Synonyms: PF-04991532; PF 04991532; PF04991532; PF-4991532; PF4991532; PF 4991532; UNII-AJ212MS2O2; CHEMBL2165620; AJ212MS2O2; SCHEMBL1711504; BDBM50394681; 6-[[(2S)-3-cyclopentyl-2-[4-(trifluoromethyl)imidazol-1-yl]propanoyl]amino]pyridine-3-carboxylic acid. Grades: 98%. CAS No. 1215197-37-7. Molecular formula: C18H19F3N4O3. Mole weight: 396.37. | |
| PF-04995274 | PF-04995274 is a 5-HT4 receptor partial agonist with Ki = 0.15 - 0.46 nM for 5-HT4 isoforms a, b, d and e, developed for the treatment of Alzheimer's disease (AD). Synonyms: (R)-4-((4-(((4-(Tetrahydrofuran-3-yloxy)-1,2-benzisoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol; PF-04995274; PF 04995274; PF04995274; PF-4995274; PF 4995274; PF4995274. CAS No. 1331782-27-4. Molecular formula: C23H32N2O6. Mole weight: 432.52. | |
| PF-05020182 | PF05020182 is novel potent and selective Kv7.2/4 potassium channel opener originated by Pfizer. It can inhibit convulsions in the MES assay at doses tested, consistent with in vitro activity measure. PF-05020182 may be applicated for adjunctive treatment of refractory epilepsy. Uses: Refractory epilepsy. Synonyms: PF05020182; PF-05020182; PF 05020182; PF5020182; PF-5020182; PF 5020182. N-[4,6-Dimethoxy-2-(4-methoxy-1-piperidinyl)-5-pyrimidinyl]-3,3-dimethyl-butanamide. Grades: 98%. CAS No. 1354712-92-7. Molecular formula: C18H30N4O4. Mole weight: 366.46. | |
| PF-05082566 | A fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein expressed in many immune cells. Synonyms: Utomilumab; PF-2566; PF-5082566; PF 2566; PF 5082566; PF2566; PF5082566. CAS No. 1417318-27-4. | |
| PF-05089771 | PF-05089771, a Nav1.7 channel blocker, has been studied to have potential effect in the treatment of chronic neuropathic pain. It is still under Phase II clinical trial. IC50: 8.6 nM. Uses: Pf-05089771 is a nav1.7 channel blocker that has been studied to have potential effect in the treatment of chronic neuropathic pain. Synonyms: PF 05089771; PF05089771; PF-05089771; 4-(2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide; SCHEMBL1095065; CHEMBL2325014; ZYSCOUXLBXGGIM-UHFFFAOYSA-N. Grades: 98%. CAS No. 1235403-62-9. Molecular formula: C18H12Cl2FN5O3S2. Mole weight: 500.35. | |
| PF 05089771 tosylate | PF 05089771 is a selective and potent inhibitor of the human voltage-gated sodium ion channel Nav1.7 with an IC50 value of 11 nM. It exhibits selectivity for Nav1.7 over other Nav1 channels (IC50 values are 0.11, 0.16, 0.85, 10, 11 and 25 μM for Nav1.2, Nav1.6, Nav1.1, Nav1.4, Nav1.3 and Nav1.5, respectively). Synonyms: 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-4-thiazolylbenzenesulfonamide tosylate; PF-05089771; PF05089771; PF 05089771 Tosylate. Grades: ≥98% by HPLC. CAS No. 1430806-04-4. Molecular formula: C18H12Cl2FN5O3S2.C7H8O3S. Mole weight: 672.56. | |
| PF 05105679 | PF-05105679 is a selective TRPM8 Antagonist with clinical efficacy in cold-related pain. IC50 value is 103 nM. It shows >100-fold selectivity for TRPM8 over a panel of receptors, ion channels and enzymes, including TRPV1 and TRPA1 ion channels. In Sep 2011, Pfizer completed a phase I trial for the treatment of neuropathic pain in Healthy volunteers in Belgium. Uses: Neuropathic pain;cold-related pain. Synonyms: PF-05105679; PF 05105679; PF05105679; PF-5105679; PF 5105679; PF5105679. 3-[[[(1R)-1-(4-Fluorophenyl)ethyl](3-quinolinylcarbonyl)amino]methyl]-benzoic acid, PF05105679, [(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid. Grades: 98%. CAS No. 1398583-31-7. Molecular formula: C26H21FN2O3. Mole weight: 428.45. | |
| PF 05180999 | PF 05180999 is a potent and selective PDE2A inhibitor (IC50 = 1 nM), with 2000-fold selectivity for PDE2A over PDE10A. PF 05180999 was evaluated for schizophrenia and migraine, but no further development has been reported since 2014. Synonyms: 4-(1-Azetidinyl)-7-methyl-5-[1-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]-imidazo[5,1-f][1,2,4]triazine; PF05180999; PF-05180999; PF 5180999; PF5180999; PF-5180999; PF 5180999; PF999; PF-999; PF 999. Grades: ≥98% by HPLC. CAS No. 1394033-54-5. Molecular formula: C19H17F3N8. Mole weight: 414.39. | |
| PF-05241328 | PF-05241328, a purely acidic molecule, is a selective inhibitor of human Nav1. 7 voltage-dependent sodium channels (IC50 = 31nM) for the treatment of pain. But PF-05241328 is studied to have poor solubility and likely solubility limited absorption. Synonyms: PF-05241328; PF 05241328; PF05241328; PF-5241328; PF 5241328; PF5241328. 1-(5-Chloro-6-(2-methylpropoxy)-3-pyridinyl)-3-methyl-N-(methylsulfonyl)-1H-indazole-5-carboxamide; 1H-Indazole-5-carboxamide, 1-(5-chloro-6-(2-methylpropoxy)-3-pyridinyl)-3-methyl-N-(methylsulfonyl)-. CAS No. 1387633-03-5. Molecular formula: C19H21ClN4O4S. Mole weight: 436.9179. | |
| PF-05297909 | PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1. Synonyms: PF-05297909; PF-5297909. | |
| PF 06260933 dihydrochloride | PF 06260933 is a highly selective, orally active and small-molecule inhibitor of MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase 4) (IC50 = 140 nM). It also inhibits MINK and TNIK (IC50= 8 and 13 nM, respectively). PF-06260933 dihydrochloride has been shown to improves fasting hyperglycemia in mice. Synonyms: 5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine dihydrochloride; PF-06260933 dihydrochloride; PF06260933 dihydrochloride; PF 06260933 dihydrochloride. Grades: ≥98% by HPLC. CAS No. 1883548-86-4. Molecular formula: C16H13ClN4.2HCl. Mole weight: 369.68. | |
| PF 06273340 | PF 06273340 is a potent and selective, orally bioavailable pan-Trk kinase inhibitor with IC50 of 6, 2, and 1 nM for Trk A, B and C, respectively. PF 06273340 is selective for Trk over a panel of ion channels, receptors and other enzymes. It shows efficacy in a rodent model of inflammatory pain. Synonyms: N-[5-[[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]carbonyl]-3-pyridinyl]-5-chloro-2-pyridineacetamide; PF-06273340; PF 06273340; PF06273340; PF-6273340; PF 6273340; PF6273340. Grades: ≥98% by HPLC. CAS No. 1402438-74-7. Molecular formula: C23H22ClN7O3. Mole weight: 479.93. | |
| PF-06372222 | PF-06372222 is a small molecule negative allosteric modulator (NAM) of glucagon receptor (GCGR), which helps treat type 2 diabetes. It is also an antagonist of the glucagon-like peptide-1 receptor GLP-1R, which can inhibit glucagon secretion and glucose-dependent insulin secretion. Synonyms: N-{4-[(R)-(3,3-Dimethylcyclobutyl)({6-[4-(Trifluoromethyl)-1h-Imidazol-1-Yl]Pyridin-3-Yl}Amino)Methyl]Benzene-1-Carbonyl}-Beta-Alanine. Grades: ≥98% by HPLC. CAS No. 1407592-99-7. Molecular formula: C26H28F3N5O3. Mole weight: 515.5. | |
| PF-06424439 Free base | PF-06424439, a imidazo-pyridin derivative, has been found to be a selective DGAT2 inhibitor that could be probably effective against dyslipidemic rodent in animal models. Synonyms: PF-06424439; PF06424439; PF 06424439; PF-6424439; PF-6424439; PF 6424439; (R)-(1-(2-(1-(4-chloro-1H-pyrazol-1-yl)cyclopropyl)-3H-imidazo[4,5-b]pyridin-5-yl)piperidin-3-yl)(pyrrolidin-1-yl)methanone. Grades: 98%. CAS No. 1469284-78-3. Molecular formula: C22H26ClN7O. Mole weight: 439.94. | |
| PF-06442609 | PF-06442609 is a potent, metabolic stable γ-secretase modulators. It displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain Aβ42 and Aβ40 were observed in a guinea pig time-course experiment. F-06442609 may be used for the treatment of Alzheimer's disease in the future. Uses: Alzheimer's disease. Synonyms: PF-06442609; PF 06442609; PF06442609; PF-6442609; PF 6442609; PF6442609. 2-((S)-1-(4-fluoro-2-((R)-1,1,1-trifluoropropan-2-yl)phenoxy)propan-2-yl)-7-(4-methyl-1H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione. Grades: 98%. CAS No. 1402002-76-9. Molecular formula: C24H24F4N4O3. Mole weight: 492.47. | |
| PF-06447475 | PF06447475 is a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the treatment of PD. Synonyms: PF06447475; PF-06447475; PF 06447475; PF6447475; PF-6447475; PF 6447475. Grades: >98%. CAS No. 1527473-33-1. Molecular formula: C17H15N5O. Mole weight: 305.33. | |
| PF-06459988 | PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including the secondary acquired resistance mutation T790M.PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. Preclinical trials in Non-small cell lung cancer in USA is on-going. Uses: Non-small cell lung cancer. Synonyms: PF-06459988; PF06459988; PF 06459988; PF-6459988; PF 6459988; PF6459988; 1-((3R,4R)-3-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one. Grades: 98%. CAS No. 1428774-45-1. Molecular formula: C19H22ClN7O3. Mole weight: 431.88. | |
| PF 06465469 | PF 06465469 is a potent, covalent inhibitor of the nonreceptor tyrosine kinase Itk (IL-2 inducible T-cell kinase) (IC50 = 2 nM). It also shows inhibitory activity against Bruton's tyrosine kinase (BTK) (IC50 = 2 nM). Synonyms: (R)-3-(1-(1-Acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-methyl-4-(1-methylethyl))benzamide; PF-06465469; PF 06465469; PF06465469; PF-6465469; PF 6465469; PF6465469. Grades: ≥95% by HPLC. CAS No. 1407966-77-1. Molecular formula: C30H33N7O2. Mole weight: 523.63. | |
| PF 06551600 malonate | PF 06551600 is a potent and selective JAK3 inhibitor with IC50 value of 33.1 μM, exhibiting >1,000-fold selectivity over JAK1 and JAK2. It inhibits phosphorylation of STAT5, induced by IL-2, IL-4, IL-7 and IL-15. It also inhibits Th1 and Th17 T-cell differentiation and function in vitro. Synonyms: 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malate. Grades: ≥98% by HPLC. CAS No. 2140301-97-7. Molecular formula: C15H19N5O·C3H4O4. Mole weight: 389.41. | |
| PF-06700841 tosylate | PF-06700841 is a potent and selective inhibitor of TYK2 and JAK1. It has the potential to treat plaque psoriasis and lupus erythematosus. Synonyms: Brepocitinib tosylate; [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone tosylate. Grades: ≥98%. CAS No. 2140301-96-6. Molecular formula: C18H21F2N7O·C7H8O3S. Mole weight: 561.61. | |
| PF-06726304 | PF-06726304 is a potent and selective EZH2 inhibitor. It also inhibits H3K27me3 with IC50 value of 15 nM. Synonyms: 5,8-dichloro-7-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one. CAS No. 1616287-82-1. Molecular formula: C22H21Cl2N3O3. Mole weight: 446.33. | |
| PF 06726304 acetate | | |
| PF-06747775 | PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung cancer through restrain EGFR-mediated signaling. It is still under Phase-I trial in Non-small cell lung cancer. Synonyms: YXX2180047; Egfr T790M inhibitor PF-06747775; PF-06747775; N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide. Grades: 98%. CAS No. 1776112-90-3. Molecular formula: C18H22FN9O2. Mole weight: 415.43. | |
| PF-06767832 | PF-06767832 is a cell permeable, potent and selective M1 muscarinic acetylcholine receptor Positive Allosteric Modulator (PAM). Synonyms: PF-06767832; PF 06767832; PF06767832; PF-6767832; PF 6767832; PF6767832; N-[(3R,4S)-3-hydroxyoxan-4-yl]-5-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyridine-2-carboxamide; GTPL9228; SCHEMBL17440029; PF-06767832; N-[(3R,4S)-3-hydroxyoxan-4-yl]-5-methyl-4-[[4-(1,3-thiazol-4-yl)phenyl]methyl]pyridine-2-carboxamide. Grades: >98%. CAS No. 1859081-58-5. Molecular formula: C22H23N3O3S. Mole weight: 409.50. | |
| PF 184 | PF 184 is a potent and selective IKKβ inhibitor (IC50 = 37 nM) with selectivity over 85 other kinases, demonstrating target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. Synonyms: 8-[[[5-Chloro-2-[3,4-dimethyl-3,4-bis(hydroxymethyl)-1-pyrrolidinyl]-4-pyridinyl]carbonyl]amino]-1-(4-fluorophenyl)-4,5-dihydro-1H-benz[g]indazole-3-carboxamide; PF-184; PF184; PF 184. Grades: ≥98% by HPLC. CAS No. 1187460-81-6. Molecular formula: C32H32ClFN6O4. Mole weight: 619.09. | |
| PF-232798 | PF-232798 is a second-generation oral CCR5 antagonist. It has broad-spectrum anti-HIV-1 activity. Synonyms: PF 232798; PF-00232798; CHEMBL1649931; 63P7W7886U; PF232798. Grades: 98%. CAS No. 849753-15-7. Molecular formula: C29H40FN5O2. Mole weight: 509.7. | |
| PF-2545920 | PF-2545920 a highly selective and potent PDE10A inhibitor. It was active with an ED50 of 1 mg/kg. Synonyms: PF-2545920; PF 2545920; PF2545920; MP-10; MP10; MP 10, Mardepodect. Grades: >98%. CAS No. 898562-94-2. Molecular formula: C25H20N4O. Mole weight: 392.45. | |
| PF 3084014 hydrobromide | PF 3084014 is a potent and selective γ-secretase inhibitor (IC50 = 1.2 and 6.2 nM in whole cell and cell-free assays, respectively). It potently reduces Aβ relative to Notch-related endpoints in vitro and in vivo. Synonyms: Nirogacestat hydrobromide; (2S)-2-[[(2S)-6,8-Difluoro-1,2,3,4-tetrahydro-2-naphthalenyl]amino]-N-[1-[2-[(2,2-dimethylpropyl)amino]-1,1-dimethylethyl]-1H-imidazol-4-yl]pentanamide dihydrobromide. Grades: ≥98% by HPLC. CAS No. 1962925-29-6. Molecular formula: C27H41F2N5O·HBr. Mole weight: 651.47. | |
| PF-3716556 | PF 3716556 is a potent and selective P-CAB with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease. Synonyms: PF-03716556; PF 03716556; PF03716556; PF-3716556; PF 3716556; PF3716556. Grades: >98%. CAS No. 928774-43-0. Molecular formula: C22H26N4O3. Mole weight: 394.47. | |
| PF-3845 | PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Synonyms: PF3845; PF-3845; PF 3845. Grades: 0.98. CAS No. 1196109-52-0. Molecular formula: C24H23F3N4O2. Mole weight: 456.469. | |
| PF-4217329 | PF-04217329 is a potent and selective EP2 receptor agonist on intraocular pressure in preclinical models of glaucoma. It is a prodrug of CP-544326. It is well tolerated in preclinical species. Uses: Pf-04217329 is useful for intraocular pressure of glaucoma. Synonyms: PF-4217329, PF 4217329, PF4217329, PF-04217329, PF04217329, PF 04217329, Taprenepag isopropyl; Propan-2-yl 2- [3- [ [ (4-pyrazol-1-ylphenyl) methyl-pyridin-3-ylsulfonylamino] methyl] phenoxy] acetate; PF4217329; PF-04217329; PF04217329; Isopropyl 2-(3-((N-(4-(1H-pyrazol-1-yl)benzyl)pyridine-3-sulfonamido)methyl)phenoxy)acetate. Grades: >98 %. CAS No. 1005549-94-9. Molecular formula: C27H28N4O5S. Mole weight: 520.60. | |
| PF-477736 | PF-477736 is a proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity. Chk1 inhibitor PF-477736 inhibits chk1, an ATP-dependent serine-threonine kinase that is a key component in the DNA replication-monitoring S/G2 checkpoint system. By overriding the last checkpoint defense against DNA damaging agent-induced lethal damage, chk1 inhibitor PF-477736 may potentiate the antitumor efficacy of various chemotherapeutic agents against tumor cells with intrinsic checkpoint defects. Synonyms: PF-477736; PF-477736; PF-477736; PF-00477736; PF00477736; PF 00477736. CAS No. 952021-60-2. Molecular formula: C22H25N7O2. Mole weight: 419.489. | |
| PF 4778574 | PF 4778574 is a potent brain penetrant AMPA receptor positive allosteric modulator (PAM) (Ki = 85 nM) that has been shown to enhance cognition in animal models. Synonyms: PF-4778574; PF 4778574; PF4778574. N-[(3R,4S)-3-[4-(5-cyano-2-thienyl)phenyl]tetrahydro-2H-pyran-4-yl]-2-propanesulfonamide. Grades: ≥98% by HPLC. CAS No. 1219633-99-4. Molecular formula: C19H22N2O3S2. Mole weight: 390.52. | |
| PF 4800567 hydrochloride | PF 4800567 is a casein kinase 1e (CK1e) selective inhibitor that is 22 fold selective for the CK1e isoform over CK1d (IC50= 32 and 711 nM for CK1ε and CK1δ respectively). Synonyms: PF 4800567 hydrochloride; PF-4800567 hydrochloride; PF4800567 hydrochloride; 3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine hydrochloride. Grades: ≥99% by HPLC. CAS No. 1391052-28-0. Molecular formula: C17H18ClN5O2.HCl. Mole weight: 396.27. | |
| PF-4840154 | PF-4840154 has been foundd to be superior than Mustard Oil as a TrpA1 agonists. IC50: 97 nM and 23 nM (EC50) for hTrpA1 and rTrpA1 respectively. Uses: Pf-4840154 has been foundd to be superior than mustard oil as a trpa1 agonists. Synonyms: PF-4840154; PF 4840154; PF4840154. CHEMBL1818218; GTPL-6309; CS-5066; GTPL 6309; CS 5066; GTPL6309; CS5066; SCHEMBL17185544; BDBM50350947. Grades: 98%. CAS No. 1332708-14-1. Molecular formula: C26H38N6O2. Mole weight: 466.62. | |
| PF-4989216 | PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhibition in cell proliferation and xenograft tumor growth in NSCLCs harboring a PIK3CA mutation, including an erlotinib resistant line, NCI-H1975. Although PF-4989216 inhibits the phosphorylation of PI3K downstream molecules in the NSCLCs with PTEN loss (NCI-H1650), PF-4989216 does not sufficiently induce anti-tumor efficacy in NCI-H1650. PF-4989216 is a potential cancer drug candidate for erlotinib resistant non-small-cell lung cancer patients with PIK3CA mutation. Synonyms: PF-4989216; PF 4989216; PF4989216. CAS No. 1276553-09-3. Molecular formula: C18H13FN6OS. Mole weight: 380.401. | |
| PF 5006739 | PF 5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε) (IC50 values are 3.9 and 17 nM, respectively). It mediates circadian rhythm phase-delaying effects in vivo. Synonyms: PF 5006739; PF5006739; PF-5006739; 4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-Pyrimidinamine; 4-{4-(4-Fluorophenyl)-1-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]-1H-imidazol-5-yl}pyrimidin-2-amine. Grades: ≥98% by HPLC. CAS No. 1293395-67-1. Molecular formula: C22H22FN7O. Mole weight: 419.46. | |
| PF 5081090 | PF 5081090, a pyridone methylsulfone hydroxamate, is a potent antibacterial agent which disrupts lipid bilayer synthesis through inhibition of LpxC (IC50 = 1.1 nM in Pseudomonas aeruginosa). Synonyms: PF 5081090; PF5081090; PF-5081090; (α R)-4-(2-Fluoro-4-methoxyphenyl)-N-hydroxy-α-methyl-α-(methylsulfonyl)-2-oxo-1(2H)-pyridinebutanamide; (2R)-4-[4-(2-Fluoro-4-methoxyphenyl)-2-oxo-2H-pyridin-1-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide. Grades: ≥98% by HPLC. CAS No. 1312473-63-4. Molecular formula: C18H21FN2O6S. Mole weight: 412.43. | |
| PF 514273 | PF 514273 is a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. The Ki for binding to CB1 and CB2 receptors is 1 nM and 10 mM, respectively. Synonyms: PF 514273; PF514273; PF-514273; 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one. Grades: ≥98% by HPLC. CAS No. 851728-60-4. Molecular formula: C21H17Cl2F2N3O2. Mole weight: 452.28. | |
| PF 5274857 hydrochloride | PF 5274857 hydrochloride is a high affinity and selective Smoothened (Smo) receptor antagonist (Ki = 4.6 nM), with >1000-fold selectivity for Smo over a panel of other receptors, ion channels and enzymes. When administered orally, it distributes through plasma to skin and tumor and remains metabolically stable. PF 5274857 also penetrates the blood-brain barrier and inhibits Smo activity in the brain. Synonyms: PF 5274857 hydrochloride; PF5274857 hydrochloride; PF-5274857 hydrochloride; 1-[4-(5'-Chloro-3,5-dimethyl[2,4'-bipyridin]-2'-yl-1-piperazinyl]-3-(methylsulfonyl)-1-propanone hydrochloride. Grades: ≥98% by HPLC. CAS No. 1613439-62-5. Molecular formula: C20H25ClN4O3S.HCl. Mole weight: 473.42. | |
| PF-562271 besylate | PF-562271 besylate is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Synonyms: PF-562271 besylate; PF 562271 besylate; PF562271 besylate. Grades: >98%. CAS No. 939791-38-5. Molecular formula: C21H20F3N7O3S.C6H6O3S. Mole weight: 665.66. | |
| PF-562271 hydrochloride | PF-562271 is an ATP-competitive, reversible inhibitor of FAK/PYK2. It blocked phosphorylation of FAK in a dose-dependent manner, inhibited migration of tumor cells, cancer-associated fibroblasts, and macrophages, resulting in suppression of tumor growth, invasion, and metastases. Synonyms: PF-562271 HCl; N-methyl-N-[3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide hydrochloride. CAS No. 939791-41-0. Molecular formula: C21H21ClF3N7O3S. Mole weight: 543.95. | |
| PF-573228 | PF-573228 is a potent and selective inhibitor of focal adhesion kinase (FAK) (IC50= 4 nM). Displays 50 - 250-fold selectivity for FAK over other protein kinases. PF573228 was recognized to affect cell adhesion and migration in many types of cells. Synonyms: PF-573228; PF 573228; PF573228; PF573,228; PF-573; 228; PF 573; 228. Grades: 0.98. CAS No. 869288-64-2. Molecular formula: C22H20F3N5O3S. Mole weight: 491.489. | |
| PF-622 | PF-622 is an irreversible FAAH inhibitor with selectivity for FAAH relative to other serine hydrolases. Synonyms: N-Phenyl-4-(quinolin-2-ylmethyl)piperazine-1-carboxamide. Grades: >98%. CAS No. 898235-65-9. Molecular formula: C21H22N4O. Mole weight: 346.4. | |
| PF 6274484 | PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). It inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R/T790M in H1975 cells (IC50s = 5.8 and 6.6 nM, respectively). Synonyms: PF 6274484; PF6274484; PF-6274484; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-2-propenamide. Grades: ≥98% by HPLC. CAS No. 1035638-91-5. Molecular formula: C18H14ClFN4O2. Mole weight: 372.78. | |
Our database is helping our users find suppliers everyday.
